Ann: Appendix 4C - quarterly-MGZ.AX, page-2

I read revenue as:
$36k from customers
$149k recovered from Lehman Bros

Whilst there was a loss with this investment it's now returned a token amount which is a positive.

What I don't see is any outgoings related to R&D.

The Letter to Shareholders mentioned continued efforts and enhancements in bringing down costs of the BCD (Blood Collection Device) and progress in bringing to market the FBN (Flash Back Needle).

Zero dollars spent suggests zero effort in the above.